Weidong Zhou

Dr. Weidong Zhou

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2014 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
RURobert K Ulrey
Robert K Ulrey
SBStephanie M Barksdale
Stephanie M Barksdale
WZWeidong Zhou
Weidong Zhou
Monique L. van HoekMonique L. van Hoek
Monique L. van Hoek
Bacteria within a biofilm are phenotypically more resistant to antibiotics, desiccation, and the host immune system, making it an important virulence factor for many microbes. Cranberry juice has long been used to prevent infections of the urinary tract, which are often related to biofilm formation. Recent studies have found that the A-type proanthocyanidins from cranberries have anti-biofilm properties against Escherichia coli.

3 November 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
WZWeidong Zhou
Weidong Zhou
MCMichela Capello
Michela Capello
CFClaudia Fredolini
Claudia Fredolini
LRLeda Racanicchi
Leda Racanicchi
LPLorenzo Piemonti
Lorenzo Piemonti
EPEmanuel F. Petricoin
Emanuel F. Petricoin

13 May 2010 in Journal of Proteome Research
Verified
Journal Article
Closed access
WZWeidong Zhou
Weidong Zhou
MCMichela Capello
Michela Capello
CFClaudia Fredolini
Claudia Fredolini
LPLorenzo Piemonti
Lorenzo Piemonti
LLLance A. Liotta
Lance A. Liotta
EPEmanuel F. Petricoin
Emanuel F. Petricoin

1 April 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
WZWeidong Zhou
Weidong Zhou
MCMichela Capello
Michela Capello
CFClaudia Fredolini
Claudia Fredolini
LPLorenzo Piemonti
Lorenzo Piemonti
LLLance A. Liotta
Lance A. Liotta
EPEmanuel F. Petricoin
Emanuel F. Petricoin

1 January 2015 in Cancer Letters
Verified
Journal Article
Closed access
WZWeidong Zhou
Weidong Zhou
LLLance A. Liotta
Lance A. Liotta
EPEmanuel F. Petricoin
Emanuel F. Petricoin

18 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
CDCatherine DeMarino
Catherine DeMarino
MCMaria Cowen
Maria Cowen
PKPooja Khatkar
Pooja Khatkar
BCBianca Cotto
Bianca Cotto
Heather BranscomeHeather Branscome
Heather Branscome
Fatah KashanchiFatah Kashanchi
Fatah Kashanchi
Of the 37.9 million individuals infected with human immunodeficiency virus type 1 (HIV-1), approximately 50% exhibit HIV-associated neurocognitive disorders (HAND). We and others previously showed that HIV-1 viral RNAs, such as trans-activating response (TAR) RNA, are incorporated into extracellular vesicles (EVs) and elicit an inflammatory response in recipient naïve cells. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), the primary cannabinoids present in cannabis, are effective in reducing inflammation. Studies show that cannabis use in people living with HIV-1 is associated with lower viral load, lower circulating CD16+ monocytes and high CD4+ T-cell counts, suggesting a potentially therapeutic application. Here, HIV-1 infected U1 monocytes and primary macrophages were used to assess the effects of CBD. Post-CBD treatment, EV concentrations were analyzed using nanoparticle tracking analysis. Changes in intracellular and EV-associated viral RNA were quantified using RT-qPCR, and changes in viral proteins, EV markers, and autophagy proteins were assessed by Western blot. Our data suggest that CBD significantly reduces the number of EVs released from infected cells and that this may be mediated by reducing viral transcription and autophagy activation. Therefore, CBD may exert a protective effect by alleviating the pathogenic effects of EVs in HIV-1 and CNS-related infections.